Evidence map›Paper›PMID 23000745›Full record

ReviewAdvanced drug delivery reviews2013

Quantum dots as a platform for nanoparticle drug delivery vehicle design.

Christine E Probst, Pavel Zrazhevskiy, Vaishali Bagalkot, Xiaohu Gao

Abstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Precision Oncology: Advances in Drug Delivery and Imaging.Recent advances in drug delivery and formulation · 2025
    Review
  13. Review
  14. Article
  15. Review
  16. Fluorescent carbon dots for sensing applications: a review.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024
    Review
  17. Article
  18. Review
  19. Review
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christine E ProbstDepartment of Bioengineering, University of Washington, Seattle, WA 98195, USA.
Pavel Zrazhevskiy
Vaishali Bagalkot
Xiaohu Gao

Funding

Sensitive and multiplexed analysis of cancer biomarkers with QD barcodesR01CA131797 · NCI · UNIVERSITY OF WASHINGTON · PI GAO, XIAOHU · 2008 to 2012
$1.6M
Targeted and traceable delivery of siRNA with nanoparticle-amphipolR01CA140295 · NCI · UNIVERSITY OF WASHINGTON · PI GAO, XIAOHU · 2009 to 2010
$647k
NCI NIH HHS R01 CA131797NCI NIH HHS R01CA131797NCI NIH HHS R01 CA140295NCI NIH HHS R01CA140295
6 · The paper itself

Abstract

Nanoparticle-based drug delivery (NDD) has emerged as a promising approach to improving upon the efficacy of existing drugs and enabling the development of new therapies. Proof-of-concept studies have demonstrated the potential for NDD systems to simultaneously achieve reduced drug toxicity, improved bio-availability, increased circulation times, controlled drug release, and targeting. However, clinical translation of NDD vehicles with the goal of treating particularly challenging diseases, such as cancer, will require a thorough understanding of how nanoparticle properties influence their fate in biological systems, especially in vivo. Consequently, a model system for systematic evaluation of all stages of NDD with high sensitivity, high resolution, and low cost is highly desirable. In theory, this system should maintain the properties and behavior of the original NDD vehicle, while providing mechanisms for monitoring intracellular and systemic nanocarrier distribution, degradation, drug release, and clearance. For such a model system, quantum dots (QDots) offer great potential. QDots feature small size and versatile surface chemistry, allowing their incorporation within virtually any NDD vehicle with minimal effect on overall characteristics, and offer superb optical properties for real-time monitoring of NDD vehicle transport and drug release at both cellular and systemic levels. Though the direct use of QDots for drug delivery remains questionable due to their potential long-term toxicity, the QDot core can be easily replaced with other organic drug carriers or more biocompatible inorganic contrast agents (such as gold and magnetic nanoparticles) by their similar size and surface properties, facilitating translation of well characterized NDD vehicles to the clinic, maintaining NDD imaging capabilities, and potentially providing additional therapeutic functionalities such as photothermal therapy and magneto-transfection. In this review we outline unique features that make QDots an ideal platform for nanocarrier design and discuss how this model has been applied to study NDD vehicle behavior for diverse drug delivery applications.

Indexed as

Drug DesignNanoparticlesQuantum DotsAnimalsDiagnostic ImagingDrug Delivery SystemsHumansIntracellular Fluid

Identifiers

PMID23000745
PMCPMC3541463

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.